APOA1 and metabolic syndrome: Compared to simvastatin alone, Tongxinluo combined with simvastatin significantly improves total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and the ApoA1/ApoB ratio in stroke patients, indicating an improvement in dyslipidemia. No noticeable adverse reactions were observed during the treatment period.